Misoprostol as agonist of IP2 receptor.
Fourteen patients with peripheral vascular disease received 200 microg of misoprostol 3 times a day during one month. The therapy with misoprostol caused clinical and biochemical improvement in all 14 patients. An elongation of pain free and maximum walking distance, shortening of pain duration and increase in arterial blood flow in both calves were observed. At the same time an activation of the fibrinolytic system, rise in the platelet aggregate ratio and increase in cAMP levels were noticed. It is suggested that misoprostol in human being caused rather activation of IP2 receptor.
Goszcz
A
A
Department of Clinical Pharmacology, Jagiellonian University Medical College, Cracow, Poland.
Bierón
K
K
Grodzińska
L
L
D001158:Arteries; D015220:Calcium Channels; D000242:Cyclic AMP / Q000097:blood; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D053496:Inositol 1,4,5-Trisphosphate Receptors; D007866:Leg / Q000098:blood supply; D016595:Misoprostol / Q000627:therapeutic use*; D010166:Palliative Care; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D012039:Regional Blood Flow / Q000187:drug effects; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D016138:Walking
D015220:Calcium Channels; D005343:Fibrinolytic Agents; C506926:ITPR1 protein, human; D053496:Inositol 1,4,5-Trisphosphate Receptors; D010975:Platelet Aggregation Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D016595:Misoprostol; D000242:Cyclic AMP